Unknown Manufacturer
Lintitript is a new, highly specific and potent CCK-A receptor antagonist.
Lintitript is a new, highly specific and potent CCK-A receptor antagonist.
Cholecystokinin (CCK) modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. Lintitript antagonizes the effect of cholecystokinin by binding to the cholecystokinin type A (CCK-A) receptor. This action presumably alters feeding habits, however the exact mechanism of action is not known.
For the treatment of pancreatic cancer and appetite disorders.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
